Dynaflow Resolve used in reserach showing potential new ways to treat pain

Chronic pain is a condition that affects approximately 20 percent of the adult population. Today, poor efficacy and…

Read more
31 Mar 2023

A new era for Dynaflow Resolve

We are excited to announce the relaunch of our high-precision ion channel screening platform Dynaflow® Resolve. With Dynaflow…

Read more
23 Mar 2023

Fluicell makes in vitro development progress in type 1 diabetes therapeutics program

Fluicell’s R&D team is demonstrating important progress in the Company’s type 1 diabetes therapeutics in vitro development and…

Read more
16 Mar 2023

Fluicell at TERMIS-EU in Manchester

We look forward to meeting everyone in the tissue engineering and regenerative medicine community in Manchester for TERMIS-EU…

Read more
14 Mar 2023

New research suggests pathway towards emergence of living cells

The cell membrane plays a crucial role for the function of biological cells. Understanding how cell-like membrane compartments…

Read more
08 Mar 2023

Fluicell publishes 2022 Q4 Year-end report

Today, February 24 2023, Fluicell publishes the Q4 Year-end report for the period January to December, 2022. The…

Read more
24 Feb 2023

Spheroid bioprinting for disease modeling

Spheroids are a powerful tool for in vitro tissue and disease modeling, with multiple applications across cancer and…

Read more
16 Feb 2023

Fluicell is growing

Do you want to be part of an innovative team pushing the boundaries in 3D bioprinting, engineered tissue-based…

Read more
30 Jan 2023

Fluicell CEO Newsletter 05, 2022

2022 has been a busy year for us at Fluicell. Not only have we this year released Biopixlar…

Read more
20 Dec 2022